Dual Contribution of Quantitative Image Analysis for the Evaluation of HER2 IHC Staining Quality, and Interpretation of HER2 Overexpression and HER2-Low Status in Breast Carcinoma

被引：0
|
作者：
Cossutta, Melissande [1 ]
Truumees, Birgit [2 ]
Papine, Alexandre [1 ]
Kristoffersen, Heidi [2 ]
Tatarinova, Ekaterina [1 ]
Homsy, Charles [1 ]
Nielsen, Soren [2 ]
Soussaline, Francoise [1 ]
机构：
[1] IMSTAR Dx, Paris, France
[2] NordiQC, Aalborg, Denmark
来源：
LABORATORY INVESTIGATION | 2024年 / 104卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
117
引用
收藏
页码：S139 / S140
页数：2
相关论文
共 50 条
  • [41] Computational pathology based HER2 expression quantification in HER2-low breast cancer
    Spitzmueller, Andreas
    Kapil, Ansh
    Shumilov, Anatoliy
    Chan, Jessica
    Konstantinidou, Lemonia
    Hassan, Zonera
    Gustavson, Mark
    Carroll, Danielle
    Della Varghese
    James, Gareth D.
    Moh, Akira
    Livingston, Andrew
    de Giorgio-Miller, Victoria
    CANCER RESEARCH, 2023, 83 (05)
  • [42] Think "HER2" different: integrative diagnostic approaches for HER2-low breast cancer
    Marchio, Caterina
    Criscitiello, Carmen
    Scatena, Cristian
    Santinelli, Alfredo
    Graziano, Paolo
    Malapelle, Umberto
    Cursano, Giulia
    Venetis, Konstantinos
    Fanelli, Giuseppe Nicolo
    Pepe, Francesco
    Berrino, Enrico
    De Angelis, Carmine
    Perrone, Giuseppe
    Curigliano, Giuseppe
    Fusco, Nicola
    PATHOLOGICA, 2023, 115 (06) : 292 - 301
  • [43] Challenges in the evaluation of HER2 and HER2-low in breast cancer in Brazil and recommendations of a multidisciplinary working group
    Gobbi, Helenice
    Carvalho, Filomena Marino
    De Brot, Marina
    Logullo, Angela Flavia
    Silva, Carlos Augusto Moreira
    Soares, Fernando Augusto
    Landeiro, Luciana
    Rahal, Rosemar
    Barrios, Carlos Henrique
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2024, 70 (10):
  • [44] Breast Cancer with Equivocal HER2 IHC: Does HER2 IHC Intensity Identify Areas with FISH Amplification?
    Hertel, Johann D.
    Kaiser-Rogers, Kathleen
    O'Connor, Siobhan
    Calhoun, Benjamin
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 173 - 173
  • [45] Understanding the spectrum of HER2 status in breast cancer: From HER2-positive to ultra-low HER2
    Ahuja, Sana
    Khan, Adil Aziz
    Zaheer, Sufian
    PATHOLOGY RESEARCH AND PRACTICE, 2024, 262
  • [46] The frequency of HER2 amplification and the percentage of membrane staining in HER2 2 + invasive carcinomas of the breast
    Andrew H. S. Lee
    Ian O. Ellis
    Virchows Archiv, 2022, 481 : 327 - 327
  • [47] The INFORM HER2 Dual ISH assay compared with FISH to determine HER2 gene status in invasive breast carcinoma
    Loftin, I. R.
    McElhinny, A.
    Miller, R.
    Garcia, C.
    Bai, I.
    Ranger-Moore, J.
    Ostrem, J.
    Padilla, M.
    Grogan, T. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (27)
  • [48] Her2 low status and response to neoadjuvant chemotherapy in Her2 negative early breast cancer
    Mattos, Bruna RaphaeliSilva
    Cesca, Marcelle Goldner
    Leite, Luciana de Moura
    Tavares, Monique Celeste
    Silva, Sinara Figueiredo
    Pirolli, Rafaela
    Fogassa, Camilla AlbinaZanco
    Silva, Erick Figueiredo
    Rocha, Francisca Giselle
    Loose, Simone Klug
    Campos, Fernando AugustoBatista
    Sanches, Solange Moraes
    de Lima, Vladmir ClaudioCordeiro
    Ponde, Noam Falbel
    CANCER RESEARCH, 2021, 81 (04)
  • [49] Evaluating Low HER2 Status in Breast Cancer Cases with Absent and Low HER2 Protein Expression
    Ardor, Gokce
    Komforti, Miglena
    Hanna, Helena
    Nassar, Aziza
    LABORATORY INVESTIGATION, 2023, 103 (03) : S94 - S95
  • [50] Quantitative image analysis (QIA) of HER2 immunohistochemistry (IHC) provides a reproducible, accurate, and cost-effective tool for HER2 assessment of breast cancers
    Judd, R. L.
    MODERN PATHOLOGY, 2007, 20 : 37A - 37A
12345